Dark

ADAP
Adaptimmune Therapeutics plc
stock NASDAQ ADR

At Close

Jun 27, 2025 3:59:30 PM EDT

0.2407USD-0.619%(-0.0015)937,866

0.00Bid 0.00Ask 0.0000Spread

Pre-market

Jun 27, 2025 9:06:30 AM EDT

0.2350USD-2.973%(-0.0072)26,693

After-hours

Jun 27, 2025 4:00:30 PM EDT

0.2350USD-2.368%(-0.0057)9,749

OverviewOptionsHistoricalExchangesShortsNews

Jan 26, 2022

08:00AM EST Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. GlobeNewswire Inc

Nov 12, 2021

07:05AM EST Adaptimmune Reports Translational Data From Co.'s Phase 1 SURPASS Trial Indicating Adding AKT Inhibitor To Manufacturing May Contribute To Sustained Antitumor Activity Presented At Society For Immunotherapy Of Cancer Benzinga

07:00AM EST - Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - GlobeNewswire Inc

Nov 11, 2021

09:02AM EST Adaptimmune Reports Results From SPEARHEAD-1 Trial In Patients With Synovial Sarcoma: Trial Will Meet Primary Endpoint Benzinga

09:00AM EST - SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year - GlobeNewswire Inc

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 4, 2021

08:19AM EDT Adaptimmune Therapeutics Q3 EPS $(0.30) Misses $(0.26) Estimate, Sales $1.20M Miss $1.37M Estimate Benzinga

08:09AM EDT Adaptimmune Therapeutics: Q3 Earnings Insights Benzinga

07:30AM EDT - Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment - GlobeNewswire Inc

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 21, 2021

08:00AM EDT Adaptimmune to Report Q3 2021 Financial Results and Business GlobeNewswire Inc

Oct 5, 2021

08:09AM EDT Adaptimmune To Present Data Updates At Upcoming CTOS And SITC Meetings Benzinga

08:00AM EDT - Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - GlobeNewswire Inc

Sep 22, 2021

07:42AM EDT Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $7 Benzinga

Sep 14, 2021

11:20AM EDT Looking Into Adaptimmune Therapeutics's Return On Capital Employed Benzinga

Sep 13, 2021

10:00AM EDT Adaptimmune Therapeutics shares were trading higher after the company announced clinical responses across five solid tumor indications with an overall response rate of 36% and promising early durability from its next-gen SURPASS trial. Benzinga

08:22AM EDT SVB Leerink Maintains Market Perform on Adaptimmune Therapeutics, Raises Price Target to $7 Benzinga

07:21AM EDT Adaptimmune Announces Clinical Responses Across Five Solid Tumor Indications With Overall Response Rate Of 36% And Promising Early Durability From Next-Generation SURPASS Trial Benzinga

07:02AM EDT Adaptimmune To Present Updated Data From Phase 1 SURPASS Trial At European Society For Medical Oncology Annual Meeting Benzinga

07:00AM EDT - Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - GlobeNewswire Inc

Sep 7, 2021

02:32PM EDT Mid-Afternoon Market Update: Dow Falls Over 200 Points; RenovoRx Shares Spike Higher Benzinga

01:12PM EDT EXCLUSIVE: Adaptimmune Therapeutics CEO Adrian Rawcliffe Tells Benzinga Co. Will Continue To Work Toward Bringing First Allogeneic Cell Therapy, A MAGE-A4 Targeted Product, To The Clinic Benzinga

10:34AM EDT SVB Leerink Maintains Market Perform on Adaptimmune Therapeutics, Raises Price Target to $6 Benzinga

07:31AM EDT Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, announced Tuesday that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group (RHHBY) to develop and commercialize allogeneic cell therapies to treat multiple oncology indications. RTTNews

07:15AM EDT Adaptimmune Enters Strategic Collaboration With Genentech To Develop Allogeneic T-cell Therapies RTTNews

07:03AM EDT Adaptimmune Enters Collaboration With Genentech To 'Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies'; Co. To Receive $150M Upfront Payment, $150M Over Next Five Years And Potential Milestones Up To $3B Benzinga

07:00AM EDT - Combining both companies cell therapy leadership and expertise, the collaboration covers the research and development of off-the-shelf cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform - GlobeNewswire Inc

Sep 5, 2021

11:24AM EDT Adaptimmune Therapeutics plc (ADAP) provided updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer. The data showed significant antitumor activity with the first-generation product targeting AFP that is encouraging for the potential of cell therapy for the treatment of liver cancer in these heavily pre-treated patients with late-stage disease. RTTNews

06:15AM EDT - One complete response, and a disease control rate of 64% with stable disease for 16 weeks in two patients, as of the data cutoff - GlobeNewswire Inc

Aug 10, 2021

09:33AM EDT Adaptimmune Limited Granted U.S. Patent Titled 'T cell receptors' Benzinga

04:50AM EDT SVB Leerink Maintains Market Perform on Adaptimmune Therapeutics, Lowers Price Target to $5 Benzinga

Aug 9, 2021

04:01PM EDT Adaptimmune Therapeutics Q2 EPS $(0.40) Down From $(0.04) YoY, Sales $3.10M Beat $1.36M Estimate Benzinga

04:00PM EDT - SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - GlobeNewswire Inc

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 28, 2021

08:11AM EDT Adaptimmune to Report Q2 2021 Financial Results and Business GlobeNewswire Inc

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

May 28, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 28, 2021 Benzinga

06:20AM EDT Barclays Initiates Coverage On Adaptimmune Therapeutics with Underweight Rating, Announces Price Target of $4 Benzinga

May 20, 2021

08:27AM EDT The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks Benzinga

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

05:01PM EDT Adaptimmune Therapeutics Announces The Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune's Phase 2 SPEARHEAD-1 Trial Benzinga

05:00PM EDT - Data will support BLA filing for afamitresgene autoleucel next year - GlobeNewswire Inc

May 11, 2021

12:32PM EDT Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows Benzinga

08:17AM EDT Adaptimmune Says Co's Mesothelin HiT Program At ASGCT 'Demonstrate Antigen-specific Tumor Cell Killing In vitro And Complete Tumor Regression In An Animal Model' Benzinga

08:00AM EDT - Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - GlobeNewswire Inc

May 6, 2021

08:43AM EDT Adaptimmune Therapeutics Q1 EPS $(0.04) Beats $(0.25) Estimate, Sales $434.00K Miss $1.83M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:30AM EDT - Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - GlobeNewswire Inc

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 5, 2021

10:06AM EDT Earnings Outlook for Adaptimmune Therapeutics Benzinga

Apr 27, 2021

04:44PM EDT Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT Benzinga

Apr 22, 2021

08:00AM EDT Adaptimmune to Report Q1 2021 Financial Results and Business GlobeNewswire Inc

Feb 25, 2021

08:10AM EST Adaptimmune Therapeutics Q4 EPS $(0.04) Beats $(0.23) Estimate, Sales $1.50M Miss $1.98M Estimate Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:30AM EST - Outlined strategy to build integrated cell therapy company and the Companys 2-2-5-2 five-year core value drivers - GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 17, 2021

10:18AM EST Adaptimmune Therapeutics shares were trading higher after Baker Bros. Advisors reported a 6.4% passive stake in the company. Benzinga

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 16, 2021

04:20PM EST Baker Bros. Advisors Reports 6.4% Passive Stake In Adaptimmune Benzinga

Feb 11, 2021

08:00AM EST Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial GlobeNewswire Inc

Nov 20, 2020

07:31AM EST Adaptimmune Therapeutics Reports Will Host Virtual Investor Day Today From 8-10 a.m. EST Benzinga

07:30AM EST - SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma - GlobeNewswire Inc

Nov 19, 2020

09:06AM EST Adaptimmune Therapeutics Highlights Durable Responses With ADP-A2M4 In Synovial Sarcoma With Confirmed Responses In 44% Of Patients And Disease Control Rate Of 94% Presented At CTOS Benzinga

09:00AM EST Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed GlobeNewswire Inc

Nov 12, 2020

08:00AM EST AdaptimmuneTherapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, willhosta virtualInvestor Dayon November20, 2020at 8AM EST/ 1PM GMT.Alink to register is available HERE and further details are on the Investor Relations tab of theAdaptimmunewebsite. GlobeNewswire Inc

Nov 9, 2020

03:20PM EST Adaptimmune Reports 2 Confirmed Responses, 5 Out Of 6 Patients With Initial Tumor Reductions From Early Dose Cohorts Of SURPASS Trial, Presented Data In Poster At Society For Immunotherapy Of Cancer Meeting Benzinga

03:18PM EST Two Confirmed Responses and Five out of Six Patients with Initial GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

11:45AM EST SVB Leerink Maintains Market Perform on Adaptimmune Therapeutics, Lowers Price Target to $6 Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:48AM EST Adaptimmune Therapeutics Q3 EPS $(0.04) Beats $(0.25) Estimate, Sales $1.20M Beat $870.00K Estimate Benzinga

07:30AM EST - Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - GlobeNewswire Inc

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 22, 2020

08:00AM EDT Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q3 2020, before the U.S. markets open on Thursday, November 5, 2020. Following the announcement, the Company will host a live teleconference and webcast at8:00 a.m. EST(1:00 p.m. GMT) on the same day (details below). GlobeNewswire Inc

Oct 16, 2020

03:27PM EDT Why Adaptimmune's Stock Is Trading Lower Today Benzinga

Oct 15, 2020

04:43PM EDT Adaptimmune Provides Full Contents Of Its SITC Abstract For Phase 1 SURPASS Trial Benzinga

04:41PM EDT Adaptimmune Provides Full Contents of its SITC Abstract for the GlobeNewswire Inc

Aug 28, 2020

10:35AM EDT Adaptimmune Highlights Presentation Of Phase 1 Trial Data With ADP-A2AFP Benzinga

Aug 6, 2020

11:06AM EDT SVB Leerink Maintains Market Perform on Adaptimmune Therapeutics, Lowers Price Target to $10 Benzinga

08:23AM EDT Adaptimmune Therapeutics Q2 EPS $(0.04) Beats $(0.23) Estimate Benzinga

07:30AM EDT - Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 - GlobeNewswire Inc

Jul 24, 2020

10:01AM EDT Adaptimmune Therapeutics shares are trading higher after the company late Thursday reported it was granted access to priority medicines regulatory support by EMA for ADP-A2M4 for treatment of Synovial Sarcoma. UPDATE: Shares have since reversed. Benzinga

Jul 23, 2020

04:00PM EDT Adaptimmune Therapeutics reports Was Granted Access To PRIority MEdicines Regulatory Support By EMA For ADP-A2M4 For Treatment Of Synovial Sarcoma Benzinga

04:00PM EDT Adaptimmune Granted Access to PRIority MEdicines (PRIME) GlobeNewswire Inc

Jul 22, 2020

08:00AM EDT Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. Following the announcement, the Company will host a live teleconference and webcast at8:00 a.m. EDT(1:00 p.m. BST) on the same day (details below). GlobeNewswire Inc